Early Prophylactic Aspirin for Aneurysmal Subarachnoid Hemorrhage

This study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate whether early prophylactic use of aspirin improves functional outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). Patients with aSAH who have undergone successful aneurysm securing will be randomly assigned to receive either aspirin plus standard care or a placebo plus standard care. The study drug will be started within 48 hours of undergone successful aneurysm securing and continued for not less than 10 days and not more than 14 consecutive days. The main goal is to compare the rate of favorable functional outcomes at 3 months between the two groups. Secondary goals include evaluating the incidence of delayed cerebral ischemia, cerebral infarction, mortality, and safety outcomes such as major bleeding events.

NCT Number	NCT07642427
Lead Sponsor	Ganzhou City People's Hospital Collaborators: The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Wannan Medical College, Nanfang Hospital, Southern Medical University, Second Affiliated Hospital of Guangzhou Medical University, Affiliated Hospital of Guangdong Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Meizhou People's Hospital, Guizhou Provincial People's Hospital, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Huang Shan People's Hospital, Jiu Jiang NO.1 People's Hospital, Ji'an Central People's Hospital, Yichun People's Hospital
Conditions	Aneurysmal Subarachnoid Hemorrhage (aSAH), Delayed Cerebral Ischemia
Enrollment	388 participants
Start Date	2026-06-01
Primary Completion	2029-05 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-11